Education Students Posters Resources Engage Destination Supporters #BeThe1To


Registration Options

Activity Date: 04/09/2019

Target Audience


Session Summary

The DSM-5 was published in 2013 with a significant change in the categorization of PTSD, from Anxiety disorder to Trauma/Stressor related disorder, based on a better understanding of the pathophysiology of the disorder. PTSD can be a disabling condition and can occur in not only war survivors, but also survivors of child abuse, violence, motor vehicle accidents, and world and national disasters to name a few. Advances in the understanding of the pathophysiology of PTSD have led to the recognition of multiple changes in neurophysiology related to PTSD which are new targets for novel therapies. In this session, participants will enhance their understanding of the pathophysiology and most up to date results of trials to enhance treatment recommendations when a standard pharmacotherapy is ineffective.

Course Requirements




Faculty Information and Disclosures

Learning Objectives

  1. Describe the current understanding of the pathophysiology of PTSD.
  2. Provide an overview of evidence-based pharmacotherapies for PTSD.
  3. Explain the quality and consistency of current trials utilizing novel pharmacotherapeutic approaches to treating PTSD.

Continuing Education Credit and Disclosures

Activity Date: 04/09/2019
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-19-030-L01-P (Knowledge)
